Accelerating Pediatric Cancer Drug Development

Challenges and Opportunities for Pediatric Master Protocols

Tahira Khan, Mark Stewart, Samuel Blackman, Raphaël Rousseau, Martha Donoghue, Kenneth J Cohen, Nita Seibel, Mark Fleury, Bouchra Benettaib, Raleigh Malik, Gilles Vassal, Gregory Reaman

Research output: Contribution to journalArticle

Abstract

Although outcomes for children with cancer have significantly improved over the past 40 years, there has been little progress in the treatment of some pediatric cancers, particularly when advanced. Additionally, clinical trial options and availability are often insufficient. Improved genomic and immunologic understanding of pediatric cancers, combined with innovative clinical trial designs, may provide an enhanced opportunity to study childhood cancers. Master protocols, which incorporate the use of precision medicine approaches, coupled with the ability to quickly assess the safety and effectiveness of new therapies, have the potential to accelerate early-phase clinical testing of novel therapeutics and which may result in more rapid approval of new drugs for children with cancer. Designing and conducting master protocols for children requires addressing similar principles and requirements as traditional adult oncology trials, but there are also unique considerations for master protocols conducted in children with cancer. The purpose of this paper is to define the key challenges and opportunities associated with this approach in order to ensure that master protocols can be adapted to benefit children and adolescents and ensure that adequate data are captured to advance, in parallel, the clinical development of investigational agents for children with cancer.

Original languageEnglish (US)
JournalTherapeutic Innovation and Regulatory Science
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Pediatrics
Pharmaceutical Preparations
Neoplasms
Clinical Trials
Drug Approval
Precision Medicine
Therapeutics
Safety

Keywords

  • clinical trial design
  • drug development
  • master protocol
  • pediatric cancer
  • regulatory policy

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

Accelerating Pediatric Cancer Drug Development : Challenges and Opportunities for Pediatric Master Protocols. / Khan, Tahira; Stewart, Mark; Blackman, Samuel; Rousseau, Raphaël; Donoghue, Martha; Cohen, Kenneth J; Seibel, Nita; Fleury, Mark; Benettaib, Bouchra; Malik, Raleigh; Vassal, Gilles; Reaman, Gregory.

In: Therapeutic Innovation and Regulatory Science, 01.01.2018.

Research output: Contribution to journalArticle

Khan, T, Stewart, M, Blackman, S, Rousseau, R, Donoghue, M, Cohen, KJ, Seibel, N, Fleury, M, Benettaib, B, Malik, R, Vassal, G & Reaman, G 2018, 'Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols', Therapeutic Innovation and Regulatory Science. https://doi.org/10.1177/2168479018774533
Khan, Tahira ; Stewart, Mark ; Blackman, Samuel ; Rousseau, Raphaël ; Donoghue, Martha ; Cohen, Kenneth J ; Seibel, Nita ; Fleury, Mark ; Benettaib, Bouchra ; Malik, Raleigh ; Vassal, Gilles ; Reaman, Gregory. / Accelerating Pediatric Cancer Drug Development : Challenges and Opportunities for Pediatric Master Protocols. In: Therapeutic Innovation and Regulatory Science. 2018.
@article{d54090f5b1c34843b8d82eefdee2b8be,
title = "Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols",
abstract = "Although outcomes for children with cancer have significantly improved over the past 40 years, there has been little progress in the treatment of some pediatric cancers, particularly when advanced. Additionally, clinical trial options and availability are often insufficient. Improved genomic and immunologic understanding of pediatric cancers, combined with innovative clinical trial designs, may provide an enhanced opportunity to study childhood cancers. Master protocols, which incorporate the use of precision medicine approaches, coupled with the ability to quickly assess the safety and effectiveness of new therapies, have the potential to accelerate early-phase clinical testing of novel therapeutics and which may result in more rapid approval of new drugs for children with cancer. Designing and conducting master protocols for children requires addressing similar principles and requirements as traditional adult oncology trials, but there are also unique considerations for master protocols conducted in children with cancer. The purpose of this paper is to define the key challenges and opportunities associated with this approach in order to ensure that master protocols can be adapted to benefit children and adolescents and ensure that adequate data are captured to advance, in parallel, the clinical development of investigational agents for children with cancer.",
keywords = "clinical trial design, drug development, master protocol, pediatric cancer, regulatory policy",
author = "Tahira Khan and Mark Stewart and Samuel Blackman and Rapha{\"e}l Rousseau and Martha Donoghue and Cohen, {Kenneth J} and Nita Seibel and Mark Fleury and Bouchra Benettaib and Raleigh Malik and Gilles Vassal and Gregory Reaman",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/2168479018774533",
language = "English (US)",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Accelerating Pediatric Cancer Drug Development

T2 - Challenges and Opportunities for Pediatric Master Protocols

AU - Khan, Tahira

AU - Stewart, Mark

AU - Blackman, Samuel

AU - Rousseau, Raphaël

AU - Donoghue, Martha

AU - Cohen, Kenneth J

AU - Seibel, Nita

AU - Fleury, Mark

AU - Benettaib, Bouchra

AU - Malik, Raleigh

AU - Vassal, Gilles

AU - Reaman, Gregory

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although outcomes for children with cancer have significantly improved over the past 40 years, there has been little progress in the treatment of some pediatric cancers, particularly when advanced. Additionally, clinical trial options and availability are often insufficient. Improved genomic and immunologic understanding of pediatric cancers, combined with innovative clinical trial designs, may provide an enhanced opportunity to study childhood cancers. Master protocols, which incorporate the use of precision medicine approaches, coupled with the ability to quickly assess the safety and effectiveness of new therapies, have the potential to accelerate early-phase clinical testing of novel therapeutics and which may result in more rapid approval of new drugs for children with cancer. Designing and conducting master protocols for children requires addressing similar principles and requirements as traditional adult oncology trials, but there are also unique considerations for master protocols conducted in children with cancer. The purpose of this paper is to define the key challenges and opportunities associated with this approach in order to ensure that master protocols can be adapted to benefit children and adolescents and ensure that adequate data are captured to advance, in parallel, the clinical development of investigational agents for children with cancer.

AB - Although outcomes for children with cancer have significantly improved over the past 40 years, there has been little progress in the treatment of some pediatric cancers, particularly when advanced. Additionally, clinical trial options and availability are often insufficient. Improved genomic and immunologic understanding of pediatric cancers, combined with innovative clinical trial designs, may provide an enhanced opportunity to study childhood cancers. Master protocols, which incorporate the use of precision medicine approaches, coupled with the ability to quickly assess the safety and effectiveness of new therapies, have the potential to accelerate early-phase clinical testing of novel therapeutics and which may result in more rapid approval of new drugs for children with cancer. Designing and conducting master protocols for children requires addressing similar principles and requirements as traditional adult oncology trials, but there are also unique considerations for master protocols conducted in children with cancer. The purpose of this paper is to define the key challenges and opportunities associated with this approach in order to ensure that master protocols can be adapted to benefit children and adolescents and ensure that adequate data are captured to advance, in parallel, the clinical development of investigational agents for children with cancer.

KW - clinical trial design

KW - drug development

KW - master protocol

KW - pediatric cancer

KW - regulatory policy

UR - http://www.scopus.com/inward/record.url?scp=85047406254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047406254&partnerID=8YFLogxK

U2 - 10.1177/2168479018774533

DO - 10.1177/2168479018774533

M3 - Article

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

ER -